CU20160038A7 - Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b - Google Patents

Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Info

Publication number
CU20160038A7
CU20160038A7 CUP2016000038A CU20160038A CU20160038A7 CU 20160038 A7 CU20160038 A7 CU 20160038A7 CU P2016000038 A CUP2016000038 A CU P2016000038A CU 20160038 A CU20160038 A CU 20160038A CU 20160038 A7 CU20160038 A7 CU 20160038A7
Authority
CU
Cuba
Prior art keywords
antigens
pharmaceutical composition
virus
antigen
hepatitis
Prior art date
Application number
CUP2016000038A
Other languages
English (en)
Other versions
CU24454B1 (es
Inventor
Santiago Jorge Agustín Aguiar
Rubido Julio César Aguilar
Blanco Sonia González
Nieto Gerardo Enrique Guillén
Pérez Enrique Iglesias
Mato Yadira Lobaina
Arias Eduardo Pentón
Hernández Jorge Valdés
Castillo Mariela Vázquez
Original Assignee
Centro De Ingeniería Genética Y Biotecnología (Biocubafarma)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/CU2017/050001 priority Critical patent/WO2017167317A1/es
Priority to MX2018011793A priority patent/MX2018011793A/es
Priority to MYPI2018703588A priority patent/MY202118A/en
Priority to EP17721509.2A priority patent/EP3437654B1/en
Priority to CU2016000038A priority patent/CU24454B1/es
Priority to EA201892212A priority patent/EA201892212A1/ru
Priority to HK19101695.5A priority patent/HK1259329B/xx
Priority to BR112018069738-9A priority patent/BR112018069738B1/pt
Priority to ES17721509T priority patent/ES2965709T3/es
Priority to UAA201810715A priority patent/UA128952C2/uk
Priority to US16/088,188 priority patent/US11491218B2/en
Application filed by Centro De Ingeniería Genética Y Biotecnología (Biocubafarma) filed Critical Centro De Ingeniería Genética Y Biotecnología (Biocubafarma)
Priority to AU2017243136A priority patent/AU2017243136B2/en
Priority to CA3017778A priority patent/CA3017778C/en
Priority to KR1020187028749A priority patent/KR20180125985A/ko
Priority to JP2018551333A priority patent/JP6981992B2/ja
Priority to CN201780033618.XA priority patent/CN109219449B/zh
Priority to TW106109533A priority patent/TWI755383B/zh
Priority to ARP170100786A priority patent/AR108009A1/es
Publication of CU20160038A7 publication Critical patent/CU20160038A7/es
Priority to ZA2018/06325A priority patent/ZA201806325B/en
Publication of CU24454B1 publication Critical patent/CU24454B1/es
Priority to US17/689,581 priority patent/US11759517B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<p>La presente invención revela una composición farmacéutica que comprende el antígeno de la superficie (HBsAg) del virus de la hepatitis B (VHB) y el antígeno de la nucleocápsida (o core, HBcAg) del propio virus. El HBcAg presente en dicha composición contiene ácido ribonucleico mensajero (ARNm) en una proporción superior al 45 porciento del total de ácido ribonucleico (ARN) de dicho antígeno. Debido a cambios en la constitución de los antígenos que la componen, la composición de la invención es útil para la prevención o el tratamiento de la hepatitis B crónica. También contempla el uso de esa composición farmacéutica en la manufactura de un medicamento para la inmunoprofilaxis o la inmunoterapia contra la infección por VHB, y su uso para incrementar la respuesta inmune contra un antígeno adicional que se co-administra con la mezcla de dichos antígenos.</p>
CU2016000038A 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b CU24454B1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
US16/088,188 US11491218B2 (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus
MYPI2018703588A MY202118A (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
EP17721509.2A EP3437654B1 (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
EA201892212A EA201892212A1 (ru) 2016-03-31 2017-03-14 Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
HK19101695.5A HK1259329B (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
AU2017243136A AU2017243136B2 (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus
MX2018011793A MX2018011793A (es) 2016-03-31 2017-03-14 Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.
UAA201810715A UA128952C2 (uk) 2016-03-31 2017-03-14 Фармацевтична композиція, яка включає поверхневі і нуклеокапсидні антигени вірусу гепатиту в
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
ES17721509T ES2965709T3 (es) 2016-03-31 2017-03-14 Composición farmacéutica que incluye los antígenos de superficie y nucleocápside del virus de la hepatitis B
BR112018069738-9A BR112018069738B1 (pt) 2016-03-31 2017-03-14 Composição farmacêutica, e, uso da mesma
CA3017778A CA3017778C (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
KR1020187028749A KR20180125985A (ko) 2016-03-31 2017-03-14 B형 간염 바이러스의 표면 및 뉴클레오캡시드 항원을 포함하는 제약학적 조성물
JP2018551333A JP6981992B2 (ja) 2016-03-31 2017-03-14 Ｂ型肝炎ウイルスの表面及び核内抗原を含む医薬組成物
CN201780033618.XA CN109219449B (zh) 2016-03-31 2017-03-14 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物
TW106109533A TWI755383B (zh) 2016-03-31 2017-03-22 包括b型肝炎病毒之表面及核殼體抗原的藥學組成物
ARP170100786A AR108009A1 (es) 2016-03-31 2017-03-30 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
ZA2018/06325A ZA201806325B (en) 2016-03-31 2018-09-20 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
US17/689,581 US11759517B2 (en) 2016-03-31 2022-03-08 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (2)

Publication Number Publication Date
CU20160038A7 true CU20160038A7 (es) 2017-11-07
CU24454B1 CU24454B1 (es) 2019-11-04

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Country Status (16)

Country Link
US (2) US11491218B2 (es)
EP (1) EP3437654B1 (es)
JP (1) JP6981992B2 (es)
KR (1) KR20180125985A (es)
CN (1) CN109219449B (es)
AR (1) AR108009A1 (es)
AU (1) AU2017243136B2 (es)
CU (1) CU24454B1 (es)
EA (1) EA201892212A1 (es)
ES (1) ES2965709T3 (es)
MX (1) MX2018011793A (es)
MY (1) MY202118A (es)
TW (1) TWI755383B (es)
UA (1) UA128952C2 (es)
WO (1) WO2017167317A1 (es)
ZA (1) ZA201806325B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548328A (ja) * 2019-09-23 2022-11-17 アセンド バイオテクノロジー インク 生分解性ナノ複合体ワクチン、ｂ型肝炎ウイルス複製およびｂ型肝炎ウイルス表面抗原分泌の抑制方法
JP2023509966A (ja) 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
EP4465999A4 (en) * 2022-02-22 2025-12-24 Carogen Corp Polyvalent Virus Vesicle (VLV) Platform for Infectious Diseases and Cancer Immunotherapy Applications
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN104338132A (zh) * 2013-07-26 2015-02-11 复旦大学 一种病毒免疫治疗药物复合物及其用途

Also Published As

Publication number Publication date
CU24454B1 (es) 2019-11-04
US11759517B2 (en) 2023-09-19
US20200297840A1 (en) 2020-09-24
BR112018069738A2 (pt) 2019-02-05
CN109219449A (zh) 2019-01-15
EP3437654B1 (en) 2023-09-20
EA201892212A1 (ru) 2019-03-29
JP6981992B2 (ja) 2021-12-17
JP2019510064A (ja) 2019-04-11
KR20180125985A (ko) 2018-11-26
AR108009A1 (es) 2018-07-04
WO2017167317A1 (es) 2017-10-05
AU2017243136B2 (en) 2022-02-17
CN109219449B (zh) 2022-08-30
US20220193228A1 (en) 2022-06-23
TWI755383B (zh) 2022-02-21
EP3437654A1 (en) 2019-02-06
ES2965709T3 (es) 2024-04-16
MY202118A (en) 2024-04-04
MX2018011793A (es) 2018-12-17
HK1259329A1 (zh) 2019-11-29
ZA201806325B (en) 2020-08-26
AU2017243136A1 (en) 2018-10-11
US11491218B2 (en) 2022-11-08
TW201735945A (zh) 2017-10-16
CA3017778A1 (en) 2017-10-05
UA128952C2 (uk) 2024-12-11

Similar Documents

Publication Publication Date Title
CU24454B1 (es) Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
PH12019550220A1 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
MX421406B (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas
UY37998A (es) Agentes antivirales contra la hepatitis b
MX2019002678A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
ECSP17022931A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alchólico
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
JP2009539965A5 (es)
MX2020011804A (es) Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.
AR081261A1 (es) Metodos para tratar afecciones virales
AR061894A1 (es) Vacunas para malaria
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
CO6300963A2 (es) Una vacuna contra la malaria que comprende p. falciparum y p. vivax
JP2019510064A5 (es)
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
UY31574A1 (es) Vacunas contra la malaria
MY191697A (en) Use of the pacap as a molecular adjuvant for vaccines
RU2017138083A (ru) Применение полимиксина в качестве антидота при отравлениях аматоксинами